80 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
-drug conjugate, completing the final stages of pre-clinical development
»STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC … ) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including
8-K
EX-99.1
STRO
Sutro Biopharma Inc
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics … at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, as we further advance our pipeline of product candidates and programs,” said Bill
8-K
EX-99.1
STRO
Sutro Biopharma Inc
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
2020 as a follow up to the encouraging interim safety data we presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference … , had initial safety and efficacy data presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29, 2019.
Based
8-K
EX-99.1
STRO
Sutro Biopharma Inc
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
in Patients with Advanced Ovarian Cancer
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference … designed cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies primarily directed at clinically-validated targets for which
8-K
EX-99.2
STRO
Sutro Biopharma Inc
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Application Boston, MA Exhibit 99.2
STRO-002-GM1 Phase 1 Clinical Trial Design First … -EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Application Boston, MA
8-K
EX-99.1
b4bzf43
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.1
j1snyy5z 5volu
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
maxxukys
8 Aug 22
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
4:32pm
8-K
81bjdd6pts7l
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
EX-99.1
fvhwdrg9
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
un79hwam
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.1
tdi06615nks
9 Sep 20
Other Events
5:23pm
8-K
EX-99.1
bg6dpadvnkhes2tv
1 Apr 19
Sutro Biopharma Reports Full Year 2018 Financial Results
10:22am
8-K
EX-99.1
8sm0vn87vt
14 Aug 19
Sutro Biopharma Reports Second Quarter 2019 Financial Results
12:00am
8-K
EX-99.1
41ju 3yrpztmtohn3gl0
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
x9unh
15 May 19
Sutro Biopharma Reports First Quarter 2019 Financial Results
7:00am
8-K
EX-99.1
6pck 530s
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
efz4 5g9ft
15 Nov 18
Sutro Biopharma Reports Third Quarter 2018 Financial Results
12:00am
8-K
EX-99.1
rhupmvimnlqcfjsmo3
19 May 21
Regulation FD Disclosure
5:00pm